Company News 29 May 2023 New Bio-manufacturing Facility Launch Event This week marks the official launch of Orthocell’s new GMP certified bio-manufacturing facility at the Company headquarters in Perth. Orthocell
Company News 29 May 2023 Appointment of John Van Der Wielen as Independent Non-Executive Chairman Orthocell has announced the appointment of Mr. John Van Der Wielen as Orthocell’s new independent Non-Executive Chairman, effective June 1,… Orthocell
Company News 26 Apr 2023 Veritas Securities Equity Research Report | April 2023 Veritas Securities Limited has released an Equity Research report valuing Orthocell (ASX: OCC) at A$0.90 per share. The report summarises… Orthocell
Company News 18 Apr 2023 Commencement of Nerve Repair Study Orthocell (ASX:OCC) has announced the commencement of a nerve repair study aimed at supporting product marketing initiatives and international regulatory… Orthocell
Media 11 Mar 2023 The West Australian | WA training for the heavyweight fight Orthocell (ASX $OCC) has been featured in a story titled “WA training for the heavyweight fight”, published in The West Australian’s… Orthocell
Media, Video 08 Mar 2023 VIDEO | Proactive Investors – March 2023 Orthocell’s Paul Anderson spoke with Andrew Scott at Proactive Investors to discuss to discuss the announcement that the Company had… Orthocell
Audio 20 Feb 2023 Finding the Front Podcast | February 2022 This week, Orthocell’s CEO and MD, Paul Anderson, joined Tim Banfield on Euroz Hartley's Finding the Front Podcast. Orthocell
Media 01 Nov 2022 Remplir™ Gains Australian Reimbursement Orthocell was featured in the widely read column, Dr Boreham’s Crucible, written by respected small cap analyst and business journalist,… Orthocell
Media 30 Sep 2022 Stockhead Investor Guide | September 2022 Orthocell was featured in the widely read column, Dr Boreham’s Crucible, written by respected small cap analyst and business journalist,… Orthocell
Company News 29 Sep 2022 Ortho-ATI™ Shoulder Tendon Study Update Orthocell has today shared positive results from the crossover extension arm of our randomised clinical trial examining the performance of… Orthocell
